The purpose of this study is to test the hypothesis that an intervention of lifestyle modification will positively impact women with breast cancer who are overweight and/or obese. To that end, our primary endpoint is to examine the effects of a practical lifestyle intervention that can be implemented by overweight or obese women (BMI greater or equal to 25) with early stage breast cancer (I-III) on outcomes such as body weight and change in BMI over the course of the study.

• Primary endpoint: To examine the effects of a practical lifestyle intervention that can be implemented by overweight or obese women (BMI greater or equal to 25) with early stage breast cancer (I-III) on outcomes such as body weight and change in BMI over the course of the study.
• Secondary endpoint: To assess the impact of such intervention on lipid profiles and hemoglobin A1C. The study group will be compared with a historical control group of patients with early stage breast cancer who are obese or overweight who were not given the intervention
• Secondary endpoint: To examine whether an active intervention program will lead into longstanding lifestyle modification in breast cancer patients with a BMI greater or equal to 25.

Inclusion Criteria:

• DCIS
• Women with stage 0 - III breast cancer (histologic type ductal or lobular)
• BMI >=25
• Patients must have completed all chemotherapy
• Patients may be on hormonal therapy or radiation therapy
• Age >= 18 years old to 89 Years old
• Patient must be medically stable and without significant impairments that would preclude following the proposed intervention regimen.
• Time of diagnosis: patients enrolled are within 1 month to 18 months post-diagnosis.

Exclusion Criteria:

• Metastatic breast cancer patients and patients with inoperable or active loco-regional disease.
• Patients following alternative/complementary diets or taking high dose antioxidant supplements.
• Patients with a physical/psychiatric impairment that would seriously impair their physical mobility.
• Patients who are currently suffering from severe nausea, anorexia or other diseases affecting health (e.g. arthritis and multiple sclerosis).
• Patients younger than 18 and older than 89 years.